A Phase II Study of Modified Lenalidomide, Bortezomib and Dexamethasone for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma
Latest Information Update: 14 Dec 2019
At a glance
- Drugs Bortezomib (Primary) ; Bortezomib (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 10 Dec 2019 Updated results of a phase 2 study of modified Lenalidomide, Bortezomib, and Dexamethasone in transplant-ineligible multiple myeloma has presented at the 61st Annual Meeting and Exposition of the American Society of Hematology
- 12 Mar 2018 Status changed from active, no longer recruiting to completed.
- 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology